ACROBiosystems Pitches 4-Day CHO-Direct Screening for AI Drug Discovery
Image
South San Francisco – October 19, 2026 -- ACROBiosystems unveiled a 4-day sequence-to-affinity screening service, CHO-DirectTM, at its ACRO Innovation Day x AI on October 13, 2026, targeting the experimental validation bottleneck in AI-driven biologics discovery. The service closes the wet-lab loop in as few as 7 days when combined with developability and characterization work.
CEO Mike Chen told attendees at The Hangar that the company's customer base has grown to 13,000. He cited rising investor interest in AI-driven drug discovery as the backdrop for the event, which followed sessions in Zurich, Shanghai (May) and a September launch event.